Company: IMNN
Filing Date: 2025-04-04
Form Type: S-1
Source: 0001641172-25-002783
Chunk: 12

Company: Imunon, Inc.
Filing Date: 2025-04-04
Form: S-1
Chunk 12
---
 Our telephone number is (609) 896-9100. Our website is www.imunon.com. The information contained on or that can be accessed through our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus or in deciding to purchase our Common Stock.

We are a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not smaller reporting companies.

| 3 |

<div align='center'>THE OFFERING</div>

| Common                                     
 Stock and common warrants offered by us    |     | Up                                                                                                                                          
 to 10,000,000 shares of Common Stock and common warrants to purchase up to 10,000,000 shares of Common Stock (or pre-funded                 
 warrants to purchase shares of Common Stock and common warrants to purchase shares of Common Stock) on a “reasonable best-efforts”          
 basis at an assumed offering price of $1.00 per share of Common Stock and accompanying common warrant (which was the closing                
 price of our Common Stock on Nasdaq on April 3, 2025) (or $1.00 per pre-funded warrant and accompanying common warrant).                    
 The shares of Common Stock or pre-funded warrants, respectively, and common warrants are immediately separable and will be issued           
 separately in this offering, but must initially be purchased together in this offering. The common warrants are exercisable beginning       
 on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the Warrant Stockholder     
 Approval will not be required and the common warrants will be exercisable on the Initial Exercise Date, have an assumed                     
 exercise price equal to $1.00 (equal to the assumed combined public offering price per share of Common Stock and accompanying               
 common warrant), and will expire five years from the